World's Best Scientists 2026 revealed!
Salvatore Siena

Salvatore Siena

Award Badge
Medicine
Italy
2023

D-Index & Metrics

Medicine

D-Index
122
Citations
90872
World Ranking
3397
National Ranking
97

Salvatore Siena publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Salvatore Siena sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 699 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Salvatore Siena D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Salvatore Siena sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 122 D-Index — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Italy Leader Award

Overview

Salvatore Siena is affiliated with the University of Milan in Italy and has a substantial research output in the field of Medicine, focusing primarily on Oncology. Their published work spans over 525 medical publications, with a significant concentration in Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Pathology and Forensic Medicine, and Radiology, Nuclear Medicine and Imaging.

Their research addresses several critical topics in cancer treatment and diagnostics. These topics include:

  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Treatments and Mutations
  • Gastric Cancer Management and Outcomes
  • HER2/EGFR in Cancer Research
  • Cancer Genomics and Diagnostics
  • Genetic factors in colorectal cancer
  • Cancer Immunotherapy and Biomarkers

Salvatore Siena has a consistent publication record in high-impact venues, frequently contributing to:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • ESMO Open
  • Cancer Research
  • Cancers

The following are some recent papers authored or coauthored by Salvatore Siena:

  • Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial, 2021, The Lancet Oncology
  • Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial, 2023, Journal of Clinical Oncology
  • EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer, 2020, Cancer Discovery
  • Precision oncology in metastatic colorectal cancer - from biology to medicine, 2021, Nature Reviews Clinical Oncology
  • Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial, 2022, Nature Medicine

Frequent collaborators in Salvatore Siena's research include:

  • Andrea Sartore-Bianchi
  • Alberto Bardelli
  • Gianluca Mauri
  • Silvia Marsoni
  • Alessio Amatu

Best Publications

  • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

    David Cunningham;Yves Humblet;Salvatore Siena;David Khayat

  • Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

    Chetan Bettegowda;Chetan Bettegowda;Mark Sausen;Rebecca J. Leary;Isaac Kinde

  • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

    Rafael G. Amado;Michael Wolf;Marc Peeters;Eric Van Cutsem

  • Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    Axel Grothey;Eric Van Cutsem;Alberto Sobrero;Salvatore Siena

  • Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

    Jean Yves Douillard;Kelly S. Oliner;Salvatore Siena;Josep Tabernero

  • Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

    Eric Van Cutsem;Marc Peeters;Salvatore Siena;Yves Humblet

  • Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

    Federica Di Nicolantonio;Miriam Martini;Francesca Molinari;Andrea Sartore-Bianchi

  • Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

    Sandra Misale;Rona Yaeger;Sebastijan Hobor;Elisa Scala

  • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter

  • Integrating liquid biopsies into the management of cancer

    Giulia Siravegna;Silvia Marsoni;Salvatore Siena;Alberto Bardelli

  • Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

    Jean Yves Douillard;Salvatore Siena;James Cassidy;Josep Tabernero

  • Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

    Marcia S Brose;Christopher M Nutting;Barbara Jarzab;Rossella Elisei

  • Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

    Robert C Doebele;Alexander Drilon;Alexander Drilon;Luis Paz-Ares;Salvatore Siena

  • Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

    Mauro Moroni;Silvio Veronese;Silvia Benvenuti;Giovanna Marrapese

  • Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial

    Andrea Sartore-Bianchi;Livio Trusolino;Cosimo Martino;Katia Bencardino

  • Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

    Giulia Siravegna;Benedetta Mussolin;Michela Buscarino;Giorgio Corti

  • Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies

    Silvia Benvenuti;Andrea Sartore-Bianchi;Federica Di Nicolantonio;Carlo Zanon

  • A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

    Andrea Bertotti;Giorgia Migliardi;Francesco Galimi;Francesco Sassi

  • GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION

    AlessandroM. Gianni;Marco Bregni;AngelikaC. Stern;Salvatore Siena

  • PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

    Andrea Sartore-Bianchi;Miriam Martini;Francesca Molinari;Silvio Veronese

Frequent Co-Authors

Andrea Sartore-Bianchi
Andrea Sartore-Bianchi University of Milan
Alberto Bardelli
Alberto Bardelli University of Turin
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Marc Peeters
Marc Peeters University of Antwerp
Fortunato Ciardiello
Fortunato Ciardiello University of Campania "Luigi Vanvitelli"
Alfredo Falcone
Alfredo Falcone University of Pisa
Vittorina Zagonel
Vittorina Zagonel Mario Negri Institute for Pharmacological Research
Sara Lonardi
Sara Lonardi Istituto Oncologico Veneto
Takayuki Yoshino
Takayuki Yoshino University of Tsukuba

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn’t always mean becoming a physician. The healthcare field offers a variety of online degree programs and certifications that can open doors to rewarding roles with flexibility and growth potential.

For those interested in healthcare data and technology, online RHIT degree programs provide a pathway into health information management, ensuring patient records are accurate and secure. If you prefer working with medical data but not directly with patients, medical coding certification online can help you quickly enter the workforce in an essential, in-demand role.

For clinical positions, nursing remains a cornerstone of healthcare. Many students are pursuing advanced nursing degrees through the cheapest online acute care nurse practitioner programs or earning an MSN online using the cheapest online MSN programs. These programs allow for specialized training and leadership opportunities, often with flexible schedules suitable for working professionals.

Exploring these online options can help you tailor your healthcare career to your interests, lifestyle, and long-term goals.

Best Scientists Citing Salvatore Siena

Trending Scientists